Source: The Lancet Oncology. Unidade: FM
Subjects: ESTUDOS RANDOMIZADOS, PLACEBO, NEOPLASIAS MAMÁRIAS (TERAPIA), ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HURVITZ, Sara A. et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. The Lancet Oncology, v. 16, n. 7, p. 816-829, 2015Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(15)00051-0. Acesso em: 29 maio 2024.APA
Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., et al. (2015). Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. The Lancet Oncology, 16( 7), 816-829. doi:10.1016/S1470-2045(15)00051-0NLM
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng L-M, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay M-A, Rao S, Pacaud LB, Taran T, Slamon D. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial [Internet]. The Lancet Oncology. 2015 ; 16( 7): 816-829.[citado 2024 maio 29 ] Available from: https://doi.org/10.1016/S1470-2045(15)00051-0Vancouver
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng L-M, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay M-A, Rao S, Pacaud LB, Taran T, Slamon D. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial [Internet]. The Lancet Oncology. 2015 ; 16( 7): 816-829.[citado 2024 maio 29 ] Available from: https://doi.org/10.1016/S1470-2045(15)00051-0